Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859001 | 0.84 | SLC40A1 (0.70) | TDP1POLBMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL1982042 | 0.84 | TDP1 (0.61) | TDP1POLBMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL29290746 | 0.84 | KDR (0.60) | TDP1POLBMAPTSMN1; SMN2HTT | |
| SCHEMBL22072823 | 0.84 | TDP1 (0.58) | TDP1POLBMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL30631857 | 0.84 | TDP1 (0.58) | TDP1POLBMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL29918706 | 0.82 | TDP1 (0.71) | TDP1POLBMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL5053488 | 0.82 | TDP1 (0.71) | TDP1POLBMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL20370082 | 0.82 | CETP (0.51) | TDP1POLBMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL30685739 | 0.81 | TDP1 (0.54) | TDP1POLBMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL30685731 | 0.81 | POLB (0.54) | TDP1POLBMAPTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106938985-B | 5-site alkenylated 8-acylaminoquinoline compound and one-pot preparation method thereof | 湖南大学 | 2020-05-05 | — | — | CN | claimed |
| CN-111320579-B | Preparation method of 8-amide-5-halogenated quinoline derivative | 常州工程职业技术学院 | 2021-06-29 | — | — | CN | disclosed |
| CN-112979545-A | Preparation method of 5-selenoquinoline amide or 5-selenoquinoline ester | 温州医科大学 | 2021-06-18 | — | — | CN | disclosed |
| CN-111320579-A | Preparation method of 8-amide-5-halogenated quinoline derivative | 常州工程职业技术学院 | 2020-06-23 | — | — | CN | disclosed |
| CN-106938985-B | 5-site alkenylated 8-acylaminoquinoline compound and one-pot preparation method thereof | 湖南大学 | 2020-05-05 | — | — | CN | disclosed |
| CN-106938985-A | A kind of 5 amide groups quinolines of alkenyl 8 and its one-pot preparation thereof | 湖南大学 | 2017-07-11 | — | — | CN | disclosed |
| WO-2007143822-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | TDP1 2777/4885POLB 751/4885MAPT 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.